However, the existing evidence did not suggest that the neoadjuvant PD‐L1 plus CTLA‐4 inhibitors therapy shows better clinical outcome than PD‐L1 treatment in melanoma, oropharynx cancer, and oral cavity squamous cell carcinoma. This evidence concerns the gene CTLA4 and melanoma.